Clinical trials: Multiple Myeloma, completed
Leukemia, Acute Leukemia
Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors
The Sharing Our Strength study is being conducted to help us understand people's experiences with hematopoietic stem cell transplantation and to test a new program designed to help people recover physically and emotionally after…
- Conditions
- Leukemia, Acute Leukemia, Acute Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00701844
- Testing
- Writing A (Experimental informative writing), Writing B (Experimental noninformative writing), Writing C (Control informative writing)
- Where
- 3 sites in United States
- Volunteers
- 315 people
- Sponsor
- University of North Carolina, Chapel Hill
Multiple Myeloma
Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma
Patients are being asked to take part in this research study because they have multiple myeloma which has relapsed after (come back), or is refractory to (unaffected by), initial therapy.
- Trial name
- NCT00135187
- Testing
- VELCADE, Doxil, Dexamethasone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose…
- Trial name
- NCT02654132
- Testing
- Elotuzumab, Pomalidomide, Dexamethasone
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 117 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
This study is for patients with newly diagnosed or relapsed multiple myeloma. The main purpose of this study is to see how their disease responds to consolidation treatment (treatment aimed at further decreasing cancer cells)…
- Trial name
- NCT00135200
- Testing
- Iodine I 131 Tositumomab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma
Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma
The purpose of this study is to explore the combination of Elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance to see what side effects it may have and how well it works for the…
- Trial name
- NCT02655458
- Testing
- Elotuzumab, Lenalidomide, autologous PBMC reconstitution
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Hearn Jay Cho
Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT00511238
- Testing
- carfilzomib
- Where
- 34 sites in United States, Canada
- Volunteers
- 312 people
- Sponsor
- Amgen
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
The purpose of this study is to see if exercise fitness testing is feasible and safe in persons over 21 years of age who have been diagnosed with a hematological malignancy and are scheduled to undergo a hematopoietic stem cell…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Hematological Malignancy, Leukemia
- Trial name
- NCT02598752
- Testing
- Symptom-limited cardiopulmonary exercise test (CPET), Resting assessment of cardiac function by echocardiography, Post-exercise assessment of cardiac function by echocardiography
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Colon Cancer
Testing a Spanish Version of a Patient Toxicity Questionnaire
Background: The Common Terminology Criteria for Adverse Events (CTCAE) is a list of toxicities and side effects that may occur when people are having cancer treatment.
- Conditions
- Breast Cancer, Colon Cancer, Lung Cancer, Lymphoma
- Trial name
- NCT01517152
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
This trial is a randomised, parallel-group, multicenter phase III study for maintenance therapy with lenalidomide in patients with multiple myeloma who were treated with high-dose therapy and autologous stem cell transplantation…
- Trial name
- NCT00891384
- Testing
- Lenalidomide
- Where
- 5 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Multiple Myeloma
Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)
This is a phase III, multicenter, prospective with a clinical benefit, open-label and randomized study to compare two different treatments : Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) versus Velcade (Bortezomib)…
- Trial name
- IFM2013-04 (NCT01971658)
- Testing
- Thalidomide®, Cyclophosphamide, Velcade®
- Where
- 62 sites in France
- Volunteers
- 358 people
- Sponsor
- Nantes University Hospital
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01718743
- Testing
- Ixazomib Citrate, Lenalidomide, Questionnaire Administration
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Agaricus Blazei Murill in Patients With Multiple Myeloma
Extract from the mushroom Agaricus blazei Murill har been shown to have strong immunomodulating properties both in cell cultures, animal models and in humans.
- Trial name
- NCT00970021
- Testing
- Intake of 60 ml agaricus daily in addition to chemotherapy
- Where
- Norway
- Volunteers
- 39 people
- Sponsor
- Ullevaal University Hospital
Multiple Myeloma
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
The purpose of this study is to compare the effects, good and bad, of two ways to treat patients with standard-risk symptomatic multiple myeloma.
- Trial name
- NCT00807599
- Testing
- Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of tocladesine in treating patients who have recurrent or…
- Trial name
- NCT00004902
- Testing
- tocladesine
- Where
- United States
- Sponsor
- Northwestern University
Multiple Myeloma
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
This phase I study will evaluate the feasibility and toxicity of weekly bortezomib in the treatment of relapsed or refractory multiple Myeloma and determine whether a twice-weekly schedule of bortezomib is effective in producing…
- Trial name
- NCT00193557
- Testing
- Bortezomib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- SCRI Development Innovations, LLC
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
This phase I trial tests the side effects and best dose of TGFbi natural killer (NK) cells (TiNK) when given together with isatuximab for the treatment of patients with multiple myeloma that has come back after a period of…
- Trial name
- NCT06203912
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Elvira Umyarova
Multiple Myeloma
Exercise in Patients With Multiple Myeloma
The overall aim is to examine whether early initiated, individualized exercise training in patients newly diagnosed with multiple myeloma, irrespective of age and current performance status, will be beneficial for the…
- Trial name
- EMMY (NCT02439112)
- Testing
- Exercise
- Where
- Denmark
- Volunteers
- 102 people
- Sponsor
- Zealand University Hospital
Acute Myeloid Leukemia, Multiple Myeloma
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
To assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a…
- Conditions
- Acute Myeloid Leukemia, Multiple Myeloma, Diffuse Large B-cell Lymphoma
- Trial name
- NCT03106428
- Testing
- MEDI7247
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 67 people
- Sponsor
- MedImmune LLC
Monoclonal Gammopathy of Undetermined Significance, Plasma Cell Myeloma
Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma
This clinical trial studies the utilization of glutamine by the bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) compared to multiple myeloma (MM).
- Trial name
- NCT03119883
- Testing
- 5-Carbon C 13-labeled Glutamine, Biospecimen Collection, Uniformly-labeled [13C]glucose
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy versus…
- Trial name
- NCT02728102
- Testing
- Tumor Cell Collection, Autologous Stem Cell Transplant, Melphalan
- Where
- 15 sites in United States
- Volunteers
- 203 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)